Partner Headlines - TEVA

  1. United Therapeutics: Will It Pass Peers In 2015?

    IBD
  2. Teva Upgraded On Strength Of Copaxone MS Drug

    IBD
  3. UPDATE: Sterne Agee Upgrades Teva Pharmaceutical

    Benzinga
  4. Teva Pharmaceutical Releases 2015 Guidance, Sees Increased Generic ...

    Benzinga
  5. Merck-Cubist Deal Going Ahead Despite Patent Setback

    IBD
  6. Weekly 52-Week Highs Highlight: ITW, ESRX, TEVA, CHD, STI

    GuruFocus
  7. Why Opko Health Is a Better Investment Than Apple

    GuruFocus
  8. Benzinga's M&A Chatter for Tuesday November 18, 2014

    Benzinga
  9. Here Are The Top 25 Analysts On Wall Street

    Benzinga
  10. Insys Q3 Beats Estimates, Helping Stock Rebound

    IBD
  11. Investors Rewarded With Treats, Not Tricks, As Dow And S&P Close ...

    Benzinga
  12. Teva ups full-year EPS outlook

    IBD
  13. UPDATE: Teva Posts Stronger-Than-Expected Q3 Profit, Lifts Forecast

    Benzinga
  14. Earnings Scheduled For October 30, 2014

    Benzinga
  15. Lannett Co. Gets Growth Rx In Generic Drugs Group

    IBD
  16. IPO Calendar: Biotech Companies Lead List Of 7 IPOs

    IBD
  17. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With ...

    Benzinga
  18. Drugmaker M&A Goes On, With Or Without Tax Inversions

    IBD
  19. Actavis Finds Rx To Grow On Busy Drugmaker M&A Scene

    IBD
  20. Teva Reports Results of Strategic Review, Sees 14 Pipeline Projects ...

    Benzinga
  21. Fast Money Halftime Report Final Trade From October 2 - Twitter ...

    Benzinga
  22. Insys Therapeutics Up On Bullish Analyst Initiation

    IBD
  23. Teva Announces UK High Court Gives Positive Judgment In The Company's ...

    Benzinga
  24. 4 Biotechs That Might Be Bought Soon

    IBD
  25. Notable Hedge Funds Disclose Additions And Reductions To Holdings

    Benzinga
  26. Jana Partners LLC Files its 13F

    Benzinga
  27. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With ...

    Benzinga
  28. Novo Nordisk, Mylan Miss Views; Mallinckrodt Beats

    IBD
  29. Did George Soros Sell His Stake In Israeli Based SodaStream Due ...

    Benzinga
  30. 5 Drug Companies Profiting From Generics

    Benzinga
  31. Top 5 Earnings Reports To Watch After The Close Tue.

    IBD
  32. Pfizer, Merck, Amgen Near Q2 Earnings Reports

    IBD
  33. George Soros Reveals His Largest Stake

    GuruFocus
  34. Sofinnova Ventures Closes $500M Fund

    FoxBusiness
  35. Israel's Market Appears Unfazed By Rising Conflict

    IBD
  36. George Soros Keeps Buying TEVA, EQT, YPF, EGN, CZR And Keeps ...

    GuruFocus
  37. UPDATE: Teva Announces FDA Acceptance of NDA For Inhaler

    Benzinga
  38. 4 Top Performing Health Care Stocks With More Potential Upside

    Benzinga
  39. Salix, Akorn, Regeneron Lead Drug Stock Rally

    IBD
  40. Top 4 Stocks In The Drug Manufacturers-Other Industry With The ...

    Benzinga
  41. Diamond Hill Capital Comments on Teva Pharmaceutical Industries ...

    GuruFocus
  42. Diamond Hill Select Fund Commentary - First Quarter 2014

    GuruFocus
  43. Teva Pharmaceutical

    IBD
  44. Generic-Drug Makers Climb Ranks; Several In Buy Range

    IBD
  45. Teva Turmoil: Shares Up, Board Trimmed, CEO To Retire

    Benzinga
  46. Wells Fargo Initiates Coverage On The Pharmaceutical Space

    Benzinga
  47. Top Guru Held Asian Companies of the First Quarter

    GuruFocus
  48. Teva to buy Labrys Biologics

    IBD
  49. Chicago sues painkiller firms

    IBD
  50. Benzinga's M&A Chatter for Tuesday June 3, 2014

    Benzinga
  51. Teva Acquiring Labrys Biologics For Migraine Drug

    IBD
  52. Richard Snow's Top Five Highlight Finance and Healthcare Sectors

    GuruFocus
  53. Benzinga's M&A Chatter for Wednesday May 7, 2014

    Benzinga
  54. ETF Outlook For Tuesday May 6, 2014 (EUFN, ITA, EIS, UAE)

    Benzinga
  55. Wrong Marketing Lesson by Big Pharma

    GuruFocus
  56. Sterne Agee Sees Mixed Factors For Teva Pharmaceutical Industries ...

    Benzinga
  57. Teva EPS tops; rivals seen?

    IBD
  58. Market Wrap For May 1: Markets Mixed To Start The New Month

    Benzinga
  59. Earnings Scheduled For May 1, 2014

    Benzinga
  60. Actavis Beats Q1 Views, Looks To Supersized Future

    IBD
  61. Actavis Reporting Q1 Earnings Amid Merger Frenzy

    IBD
  62. US Stock Futures Up Ahead Of Earnings, Consumer Confidence Data

    Benzinga
  63. Morning Market Losers

    Benzinga
  64. Benzinga's Top #PreMarket Losers

    Benzinga
  65. UPDATE: Teva, Oncogenex Offer Top-Line Survival Results of Phase ...

    Benzinga
  66. Nasdaq Could Be in for a Bounce

    FoxBusiness
  67. Actavis got a Pfizer

    IBD
  68. Teva Settles Patent Litigation with Pfizer on Celebrex; Has Received ...

    Benzinga
  69. Sterne Agee Sees Teva Pharmaceutical Outperformance Continuing

    Benzinga
  70. Teva Unveils Generic Lunesta Tablets in US

    Benzinga
  71. Teva Announces First Approval and Launch of Generic Lovaza® Capsules ...

    Benzinga
  72. Market Wrap For April 7: Bears In Complete Control As Markets ...

    Benzinga
  73. Citigroup Slaps $70 Price Target on Teva, Highest on Street

    Benzinga
  74. Market Wrap For March 31: Stocks Rally As Yellen Confirms Support ...

    Benzinga
  75. Analyst Offers Insight on Favorable FDA Ruling for Teva Pharma

    Benzinga
  76. Market Wrap For March 28: Markets Still Positive Despite Giving ...

    Benzinga
  77. Teva Offers Most Attractive Risk-Reward Profile, Citigroup Says

    Benzinga
  78. UPDATE: Goldman Sachs Upgrades Teva Pharmaceutical Industries

    Benzinga
  79. Forest Laboratories' Recovery

    GuruFocus
  80. Should You Buy Actavis?

    GuruFocus
  81. Horizon Pharma Banks On Two-For-One Arthritis Drugs

    IBD
  82. UPDATE: JP Morgan Upgrades Teva Pharmaceuticals

    Benzinga
  83. UPDATE: Morgan Stanley Upgrades Teva Pharmaceutical Industries ...

    Benzinga
  84. Benzinga's Top Upgrades

    Benzinga
  85. US Stock Futures Edge Higher Ahead Of Consumer Sentiment Report

    Benzinga
  86. Pfizer Loses Patent On Celebrex, Plans To Appeal

    IBD
  87. Pfizer Loses Bid to Hold Celebrex Exclusivity to '15

    FoxBusiness
  88. Will Horizon Pharma Spike Again On Quarterly Report?

    IBD
  89. UPDATE: Barclays Upgrades Teva Pharmaceutical Industries Limited ...

    Benzinga
  90. Teva upgraded on drug launch

    IBD
  91. Teva Upgraded On Strong Launch Of Next-Gen Copaxone

    IBD
  92. Weekly 52-Week Highs Highlight: COV, EQT, XLNX, TEVA

    GuruFocus
  93. UPDATE: CRT Capital Initiates Coverage on OncoGenex

    Benzinga
  94. Top 4 NYSE Stocks In The Drug Manufacturers-Other Industry With ...

    Benzinga
  95. Insys Recovers From Stock Hit Tied To Fed Probe

    IBD
  96. Generic-Drug Makers Actavis, Mylan To Report Q4 Soon

    IBD
  97. #PreMarket Primer: Friday, February 7: Jobs Friday

    Benzinga
  98. Teva Pharmaceuticals A Giant In Generic Drugs

    IBD
  99. UPDATE: Teva Pharmaceutical Posts Upbeat Q4 Earnings

    Benzinga
  100. Earnings Scheduled For February 6, 2014

    Benzinga
Trading Center